Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Dundee
With
Chief Scientist Office of the Scottish Government
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male and female volunteers with stable mild intermittent or mild persistent asthma.
Stable defined as: FEV1 (Forced Expiratory Volume in 1second) \>80% predicted with diurnal FEV1 variation \<30% when LABA (Long Acting Beta Agonist) washed out.
Methacholine PC20 \<4mg/ml.
Ability to perform spirometry, IOS (Impulse Oscillometry), bronchial challenge and all domiciliary measurements.
Ability to obtain Informed consent.
Mild to Moderate Asthmatics taking ≤1000μg BDP (Beclomethasone Diproprionate) per day or equivalent.
Withhold LABAs for 1 week prior to study.
You may not be if
Uncontrolled symptoms of asthma.
Resting BP (Blood Pressure) \<110 systolic or HR (Heart Rate)\<60.
Pregnancy or lactation.
Known or suspected sensitivity to the IMP (Investigational Medicinal Product)(s).
Inability to comply with protocol.
Any degree of heart block.
Rate limiting medication including β blockers, rate limiting Calcium - Channel Blockers and Amiodarone.
Any other clinically significant medical condition that may either endanger the health or safety of the participant, or jeopardise the protocol.
An asthma exacerbation within the last 6 months.
Clareo Health | Beta Blockers for the Treatment of Asthma
